Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02879305 · ClinicalTrials.gov registry record · Phase 3
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,964
- Enrollment target
NCT02879305 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,964 participants.
The verdict
NCT02879305, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,964 participants
- Enrollment target
Study Summary
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
Interventions
- DRUG Placebo
- DRUG Daprodustat
- DRUG rhEPO
- DRUG Iron therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,964 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02879305
The ClinicalTrials.gov registry entry for NCT02879305 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,964 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02879305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02879305 about?
NCT02879305 is a clinical study titled "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)". The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
What is the current status of trial NCT02879305?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,964 participants. The study started on 2016-09-28. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT02879305?
The interventions under investigation include: Placebo (DRUG), Daprodustat (DRUG), rhEPO (DRUG), Iron therapy (DRUG).
Who is sponsoring clinical trial NCT02879305?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.